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Abstract  
BACKGROUND: Carnitine palmitoyltransferase II deficiency (CPT II) is an autosomal recessive disorder and the 
most common inherited disorder of mitochondrial long-chain fatty acid oxidation, characterised by attacks of 
myalgia and myoglobinuria. The most common “classic” myopathic form occurs in young adults and is 
characterised by recurrent episodes of rhabdomyolysis triggered by prolonged exercise, fasting or febrile illness. 
CASE PRESENTATION: We present a case of a 22-year-old Caucasian male admitted to our hospital with fever, 
dyspnea, fatigue, myalgia and dark urine (brown-coloured). The symptoms appeared after viral infection followed 
by fever. Acute kidney injury (AKI) developed as a complication, and there was a need for treatment with 
hemodialysis. At the clinical presentation, the patient had plasma creatine kinase (pCK) level of 130.383 U/L and 
plasma myoglobin level over 5000 µg/L. Genetic testing (molecular analysis) confirmed the diagnosis of inherited 
rhabdomyolysis, a metabolic disorder of carnitine palmitoyltransferase II deficiency. A previous episode with the 
same symptoms, the patient had four years ago but did not ask for medical treatment. The patient was 
discontinued from hemodialysis because of the resolution of acute kidney injury. The patient was discharged from 
the hospital in good condition, with a recommendation about his future lifestyle in order to prevent similar 
episodes. 
CONCLUSION: Every patient presenting with myalgia, dark urine (brown-coloured), high level of pCK and 
development of AKI requiring hemodialysis, should be explored for inherited rhabdomyolysis induced by CPT II 
deficiency. 
 
 
 
 
 
 
 
 
Introduction 
 
Carnitine palmitoyltransferase II (CPT II) 
deficiency is a genetic disorder of mitochondrial fatty 
acid oxidation. Long-chain fatty acids are required for 
fueling the skeletal muscles, and they are only able to 
cross mitochondrial membrane after esterification with 
carnitine in a reaction with the enzyme CPT II [1] [2]. 
The damages are the result of an increased 
intracellular free ionised cytoplasm and mitochondrial 
calcium. This might be caused by depletion of 
adenosine triphosphate (ATP), and/or by direct injury 
and rupture of the plasma membrane. ATP depletion 
leads to myocyte injury and the release of intracellular 
muscle constituents, including creatine kinase (CK) 
and other muscle enzymes, myoglobin, and various 
electrolytes [3]. Three types of CPT II deficiency are 
recognised: a lethal neonatal form, a severe infantile 
hepatocardiomuscular form and myopathic form in 
which the onset ranges from infancy to adulthood [1] 
[2] [4]. The third one is the most common disorder of 
lipid metabolism affecting skeletal muscle and is the 
most frequent cause of hereditary myoglobinuria. 
In vivo investigation of fatty acid oxidation in 
CPT II deficiency individuals, by indirect calorimetry 
and stable isotope methodology, shows impaired 
oxidation of long chain fatty acids during low-intensity 
exercise, with normal oxidation at rest. In addition, this 
method can only highlight low-fat oxidation but not 
diagnose CPT II deficiency. Almost all individuals with 
the myopathic form suffer from myalgia. 
Approximately 60% of them have muscle weakness 
during the attacks. The muscle cramps also occur 
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during the attacks, although they are not typical of this 
disease [5]. Myoglobinuria with brown-coloured urine 
occurs during the attacks in approximately 75% of the 
patients [6]. The first description of this disease in 
adults with exercise-induced rhabdomyolysis was 
made by Di Mauro in 1973 [7]. The symptoms start in 
childhood, whereas the attacks with myoglobinuria 
mostly emerge in adolescence or early adulthood. The 
most severe complications are massive 
rhabdomyolysis followed by acute kidney injury (AKI) 
requiring hemodialysis, acute hepatic lesion, 
respiratory insufficiency and paroxysmal heart 
arrhythmias. 
 
 
Case presentation 
 
We present a case of a 22-year-old 
Caucasian male, who until this hospital admission, 
had never asked for medical treatment. From the 
family medical history, the father of the patient died 10 
years ago from cancer. The patient presented with 
fever, dyspnea, myalgia, fatigue, and dark urine 
(brown-coloured), followed by the development of 
acute kidney injury with oliguria. The laboratory 
analyses showed: plasma creatine kinase (pCK) level 
of 130.383 U/L, plasma myoglobin level over 5000 
µg/L, plasma lactate dehydrogenase (pLDH) level of 
2607 U/L, plasma alanine aminotransferase (pALT) 
level of 1104 U/L, plasma aspartate aminotransferase 
(pAST) level of 2920 U/L, plasma creatinine level of 
574 µmol/L, and plasma blood urea nitrogen level of 
20.6 mmol/L. The patient was initiated with 
hemodialysis treatment via a temporary vascular 
access-venous femoral catheter. The hemodialysis 
sessions were performed without complications. 
Genetic testing (molecular analysis) for an 
inherited metabolic disorder was done, and there was 
a confirmation of the diagnosis CPT II deficiency. 
Deoxyribonucleic acid (DNA) sequencing analysis of 
exons 3 of the CPT II gene revealed that the patient 
had homozygote active mutation TCG>TTG for Ser 
113 Leu and it was associated with family 
myoglobinuria. 
During the hospitalisation, six hemodialysis 
treatments were performed. At day 12 of the 
hospitalisation, the patient was discontinued from the 
hemodialysis because of recurrence of diuresis with 
declining plasma levels of creatinine and blood urea 
nitrogen (Table 1). Ultrasonography examination of 
the kidneys showed normal kidney size and 
echogenic structure. Urine culture was sterile. The 
immunological testing (ANA, anti-dsDNA, cANCA) 
were negative. Continuous abdominal pain in the 
epigastric region with vomitus was also present. With 
upper digestive endoscopy, chronic gastritis with 
superficial ulcers was diagnosed. During the whole 
period, the plasma levels of calcium and potassium 
were in the normal range (Table 1). At the hospital 
admission the level of myoglobin was over 5000 µg/L, 
but at the end of the hospitalisation, it was 258.6 µg/L. 
Also, the level of pCK was 130.383 U/L, but at the 
end, it was 329 U/L (Table 1). 
Table 1: Presentation of the laboratory findings during the 
patient’s hospitalisation 
 
14 
march 
15 
march 
16 
march 
17 
march 
18 
march 
19 
march 
24 
march 
26 
march 
27 
march 
30 
march 
 
Day (1) Day (2) Day (3) Day (4) Day (5) Day (6) 
Day 
(11) 
Day 
(13) 
Day 
(14) 
Day 
(17) 
P CK U/L 
 
130.383 38.251 9.865 
 
1.306 155 
  
329 
P CK-MB U/L 
 
1626 473 
  
30 
    P Myoglobin 
µg/L 
 
>500 >5000 >3000 
 
1297 258.6 
   P LDH U/L 
 
2607 1554 
  
471 460 
   P AST U/L 
 
2920 1590 869 
 
139 46 
   P ALT U/L 
 
1104 955 697 
 
357 134 
   P Creatinine 
µmol/L 574 555 601 
    
641 671 480 
P Urea mmol/L 
 
20.6 21.7 
    
11.5 
  P Potassium 
mmol/L 4.7 5 
 
4.2 
 
4.1 
 
3.8 3.9 4 
P Calcium 
mmol/L 
 
2.08 
 
2.32 
 
2.3 2.33 2.34 
 
2.35 
P Phosohat 
mmol/L 
 
2.2 
        White blood 
cells count 
10*9/L 
 
25.2 16.1 13.4 15.9 
 
18.1 
  
10.1 
Platelet count 
10*9/L 
 
214 198 194 246 
 
341 
  
412 
P Total proteins 
g/L 
 
58 62 61 
 
59 67 
   P Albumins g/L 
 
38 37 35 
 
35 38 
   P Globulins g/L 
 
20 25 26 
 
24 29 
   C3 g/L 
     
1.27 
    C4 g/L 
     
0.204 
    Diuresis ml 
 
100 
 
100 
 
200 500 1900 2800 4800 
 
The patient was discharged from the hospital 
in good condition, with recommendations about his 
future lifestyle in order to prevent similar episodes. 
The advice was given to his family members about the 
genetic metabolic disorder, CPT II deficiency. 
 
 
Discussion 
 
We presented a patient with fever, dyspnea, 
myalgia, fatigue, and dark urine (brown-coloured), 
with the acute hepatic lesion, without respiratory or 
heart failure. The symptoms occurred after a viral 
infection followed by fever. The patient also developed 
acute kidney injury requiring hemodialysis. Laboratory 
data suggested that it was due to massive 
rhabdomyolysis. The diagnosis was established by 
genetic testing (molecular analysis) for an inherited 
metabolic disorder which confirmed the diagnosis 
CPT II deficiency. 
A few years ago, at the Hospital of Cardiology 
in Skopje-Macedonia, another patient (20 years old) 
with the same genetic inherited metabolic disorder 
(CPT II deficiency) was treated. The patient 
developed acute kidney injury, acute hepatic lesion, 
respiratory insufficiency and cardiomyopathy with 
volume overload. He was treated with 
plasmapheresis, hemodialysis and supportive therapy. 
The patient was discharged from the hospital in good 
condition with advice for a lifestyle modification [8]. 
One clinical study summarizes the clinical features of 
this disease, analysing data of 28 patients with 
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biochemically and genetically confirmed CPT II 
deficiency. It is noticeable that exercise was the 
most important trigger factor for attacks. The authors 
also noted that infections were more frequent trigger 
factors than fasting. CPT II deficiency was 
characterised with a male predominance of 86%, due 
to the X-chromosomal modifier genes or hormonal 
factors such as estrogen that might be a regulator of 
CPT [9]. Another clinical study presented that this 
enzymatic defect was detected in 47% of 77 patients, 
who underwent biopsy for idiopathic myoglobinuria. 
The carnitine palmitoyltransferase II deficiency was 
the most common disorder in the group of the 
biopsied patients [10]. 
 It is necessary to detect the aetiology of 
rhabdomyolysis and start with the medical treatment. 
Although some genetic mutations have already been 
defined, the prevalence of these mutations is still 
unknown. It might be that the mutant enzyme is 
thermolabile in the adult form, causing the episodes of 
rhabdomyolysis during the acute febrile illness [11]. 
Diagnosing CPT II deficiency can be done by 
acylcarnitine analysis using tandem mass 
spectrometry (peak at C16 is indicative of the 
condition). Measurement of the CPT II activity can be 
performed as well as many laboratory findings, such 
as low carnitine levels, increased serum plasma 
creatine kinase and transaminase, which can be 
associated with the disease. For a definitive 
diagnosis, sequencing of the CPT II gene for mutation 
analysis is recommended [8]. Prenatal diagnosis may 
be offered for pregnancies at a 1/4 risk of 
infantile/severe-type CPT II deficiency [2]. 
Prevention includes protection from infections, 
avoidance of some medications (ibuprofen, diazepam, 
valproic acid) and general anaesthesia, toxins, heat 
and stress. Treatment is based on avoidance of 
fasting (more frequent meals) and exercise. A low-fat 
diet enriched with medium chain triglycerides and 
carnitine is recommended [12]. During acute 
infections, an infusion of glucose can be administered. 
Oral carnitine supplementation can be considered as 
an adequate therapy. The medium-chain fatty acid 
triheptanoin may be effective in the adult-onset CPT II 
deficiency [13]. 
In conclusion, inherited genetic metabolic 
disorder (CPT II deficiency) followed by massive 
rhabdomyolysis with acute kidney injury requiring 
hemodialysis might be a life-threatening condition. It 
could cause severe organ damage with a need for 
intensive medical treatment. The definitive diagnosis 
of this condition is achieved by genetic testing. 
Whenever a patient suffers from recurrent episodes of 
myalgia, followed by myoglobinuria due to 
rhabdomyolysis, the possibility of the presence of this 
rare condition should be considered. 
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